CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Titan Pharmaceuticals, Inc. - TTNP CFD

    0.41
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 0.4
    Open* 0.41
    1-Year Change* -55.91%
    Day's Range* 0.4 - 0.41
    52 wk Range 0.31-1.09
    Average Volume (10 days) 30.29K
    Average Volume (3 months) 787.50K
    Market Cap 5.41M
    P/E Ratio -100.00K
    Shares Outstanding 15.02M
    Revenue 306.00K
    EPS -0.41
    Dividend (Yield %) N/A
    Beta 1.35
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 9, 2023 0.41 0.00 0.00% 0.41 0.41 0.41
    Nov 7, 2023 0.40 -0.01 -2.44% 0.41 0.41 0.40
    Nov 6, 2023 0.42 0.00 0.00% 0.42 0.42 0.41
    Nov 3, 2023 0.45 0.00 0.00% 0.45 0.45 0.45
    Oct 30, 2023 0.40 0.01 2.56% 0.39 0.40 0.39
    Oct 27, 2023 0.42 0.00 0.00% 0.42 0.42 0.42
    Oct 26, 2023 0.41 -0.02 -4.65% 0.43 0.43 0.41
    Oct 25, 2023 0.45 0.04 9.76% 0.41 0.48 0.41
    Oct 24, 2023 0.42 0.00 0.00% 0.42 0.54 0.42
    Oct 20, 2023 0.41 0.02 5.13% 0.39 0.41 0.39
    Oct 19, 2023 0.40 -0.03 -6.98% 0.43 0.43 0.40
    Oct 17, 2023 0.46 -0.01 -2.13% 0.47 0.47 0.44
    Oct 16, 2023 0.44 -0.01 -2.22% 0.45 0.47 0.43
    Oct 13, 2023 0.45 0.00 0.00% 0.45 0.45 0.42
    Oct 12, 2023 0.44 0.00 0.00% 0.44 0.44 0.44
    Oct 11, 2023 0.42 0.00 0.00% 0.42 0.43 0.42
    Oct 10, 2023 0.42 0.01 2.44% 0.41 0.42 0.38
    Oct 9, 2023 0.41 -0.03 -6.82% 0.44 0.44 0.41
    Oct 6, 2023 0.42 -0.01 -2.33% 0.43 0.43 0.42
    Oct 5, 2023 0.44 -0.01 -2.22% 0.45 0.45 0.43

    Titan Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.557 1.526 4.838 2.605 6.618
    Revenue 0.557 1.526 4.838 2.605 6.618
    Total Operating Expense 10.792 10.219 12.27 10.255 14.882
    Selling/General/Admin. Expenses, Total 6.034 4.989 5.801 5.401 6.866
    Research & Development 4.758 5.692 5.916 5.08 7.478
    Operating Income -10.235 -8.693 -7.432 -7.65 -8.264
    Interest Income (Expense), Net Non-Operating 0.053 0.001 0.283 0.143 -0.753
    Other, Net -0.024 -0.084 -0.258 0.017 -0.006
    Net Income Before Taxes -10.206 -8.776 -7.407 -7.49 -9.023
    Net Income After Taxes -10.206 -8.776 -7.407 -7.49 -9.023
    Net Income Before Extra. Items -10.206 -8.776 -7.407 -7.49 -9.023
    Net Income -10.206 -8.776 -18.242 -16.458 -9.023
    Income Available to Common Excl. Extra. Items -10.206 -8.776 -7.407 -7.49 -9.308
    Income Available to Common Incl. Extra. Items -10.206 -8.776 -18.242 -16.458 -9.308
    Diluted Net Income -10.206 -8.776 -18.242 -16.458 -9.308
    Diluted Weighted Average Shares 13.434 9.73 3.773 0.766 0.39863
    Diluted EPS Excluding Extraordinary Items -0.75971 -0.90195 -1.96316 -9.77807 -23.3502
    Diluted Normalized EPS -0.75971 -0.96989 -1.91519 -10.0731 -23.3502
    Total Extraordinary Items 0 -10.835 -8.968 0
    Cost of Revenue, Total 0 0.199 0.472 0 0.538
    Gross Profit 0.557 1.327 4.366 2.605 6.08
    Total Adjustments to Net Income -0.285
    Unusual Expense (Income) 0 -0.661 0.081 -0.226
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.083 0.098 0.121 0.095 0.15
    Revenue 0.083 0.098 0.121 0.095 0.15
    Cost of Revenue, Total 0 0 0
    Gross Profit 0.121 0.095 0.15
    Total Operating Expense 1.671 1.795 2.732 2.738 2.592
    Selling/General/Admin. Expenses, Total 1.229 1.234 1.289 1.806 1.618
    Research & Development 0.442 0.561 1.443 0.932 0.974
    Operating Income -1.588 -1.697 -2.611 -2.643 -2.442
    Interest Income (Expense), Net Non-Operating 0.007 0.022 0.027 0.021 0.005
    Other, Net -0.005 0 0.018 -0.016 -0.025
    Net Income Before Taxes -1.586 -1.675 -2.566 -2.638 -2.462
    Net Income After Taxes -1.586 -1.675 -2.566 -2.638 -2.462
    Net Income Before Extra. Items -1.586 -1.675 -2.566 -2.638 -2.462
    Total Extraordinary Items
    Net Income -1.586 -1.675 -2.566 -2.638 -2.462
    Income Available to Common Excl. Extra. Items -1.586 -1.675 -2.566 -2.638 -2.462
    Income Available to Common Incl. Extra. Items -1.586 -1.675 -2.566 -2.638 -2.462
    Diluted Net Income -1.586 -1.675 -2.566 -2.638 -2.462
    Diluted Weighted Average Shares 15.016 15.016 14.643 14.629 13.692
    Diluted EPS Excluding Extraordinary Items -0.10562 -0.11155 -0.17524 -0.18033 -0.17981
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.10562 -0.11155 -0.17524 -0.18033 -0.17981
    Unusual Expense (Income) 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 3.603 7.229 7.328 8.308 13.301
    Cash and Short Term Investments 2.937 6.037 5.413 5.223 9.295
    Cash 6.037 5.413 5.223 9.295
    Total Receivables, Net 0.036 0.112 0.884 0.993 1.836
    Accounts Receivable - Trade, Net 0.036 0.112 0.884 0.993 1.836
    Prepaid Expenses 0.314 0.48 0.522 1.094 0.547
    Total Assets 4.058 7.994 8.087 9.522 14.095
    Property/Plant/Equipment, Total - Net 0.407 0.717 0.759 1.214 0.794
    Property/Plant/Equipment, Total - Gross 2 2.114 3.307 5.897 5.233
    Accumulated Depreciation, Total -1.593 -1.397 -2.548 -4.683 -4.439
    Total Current Liabilities 2.63 2.669 4.223 3.6 3.452
    Accounts Payable 0.695 0.795 1.253 1.401 1.526
    Accrued Expenses 1.61 0.435 0.683 1.39 1.086
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 2.695 2.856 4.555 8.089 7.264
    Total Long Term Debt 0 0 0.332 4.019 3.787
    Other Liabilities, Total 0.065 0.187 0 0.47 0.025
    Total Equity 1.363 5.138 3.532 1.433 6.831
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.015 0.01 0.007 0.057 0.013
    Additional Paid-In Capital 387.609 381.183 370.804 350.413 339.397
    Retained Earnings (Accumulated Deficit) -386.261 -376.055 -367.279 -349.037 -332.579
    Total Liabilities & Shareholders’ Equity 4.058 7.994 8.087 9.522 14.095
    Total Common Shares Outstanding 15.0163 9.91416 7.13907 1.91244 0.43363
    Other Current Assets, Total 0.21 0.307 0.181 0 0.361
    Current Port. of LT Debt/Capital Leases 0 0.327 0 0.527
    Long Term Debt 0 0.332 4.019 3.787
    Total Inventory 0.106 0.293 0.328 0.998 1.262
    Other Current Liabilities, Total 0.325 1.439 1.96 0.809 0.313
    Other Long Term Assets, Total 0.048 0.048
    Cash & Equivalents 2.937
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 9.899 0.498 1.785 3.603 5.747
    Cash and Short Term Investments 8.096 0.105 1.136 2.937 4.45
    Cash & Equivalents 8.096 0.105 1.136 2.937 4.45
    Total Receivables, Net 1.526 0.009 0.008 0.036 0.049
    Accounts Receivable - Trade, Net 0.026 0.009 0.008 0.036 0.049
    Total Inventory 0 0 0.106 0.106 0.46
    Prepaid Expenses 0.244 0.229 0.406 0.314 0.512
    Other Current Assets, Total 0.033 0.155 0.129 0.21 0.276
    Total Assets 9.999 0.812 2.168 4.058 6.276
    Property/Plant/Equipment, Total - Net 0.1 0.133 0.335 0.407 0.481
    Total Current Liabilities 1.866 1.846 2.447 2.63 2.63
    Accounts Payable 0.407 0.597 0.567 0.695 0.812
    Accrued Expenses 0.887 0.807 1.595 1.61 0.687
    Notes Payable/Short Term Debt 0.5 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 0.072 0.442 0.285 0.325 1.131
    Total Liabilities 1.866 1.846 2.48 2.695 2.726
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Total Equity 8.133 -1.034 -0.312 1.363 3.55
    Common Stock 0.015 0.015 0.015 0.015 0.015
    Additional Paid-In Capital 397.977 388.473 387.609 387.609 387.23
    Retained Earnings (Accumulated Deficit) -389.86 -389.522 -387.936 -386.261 -383.695
    Total Liabilities & Shareholders’ Equity 9.999 0.812 2.168 4.058 6.276
    Total Common Shares Outstanding 15.0163 15.0163 15.0163 15.0163 14.6292
    Other Liabilities, Total 0 0 0.033 0.065 0.096
    Cash
    Other Long Term Assets, Total 0 0.181 0.048 0.048 0.048
    Preferred Stock - Non Redeemable, Net 0.001
    Total Preferred Shares Outstanding 0.95
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -10.206 -8.776 -18.242 -16.458 -9.023
    Cash From Operating Activities -8.183 -7.899 -17.203 -15.445 -8.431
    Cash From Operating Activities 0.196 0.221 0.292 0.244 0.38
    Non-Cash Items 1.449 0.875 -0.271 -0.192 0.62
    Changes in Working Capital 0.378 -0.219 1.018 0.961 -0.408
    Cash From Investing Activities 0 -0.023 -0.54 -0.256 -0.416
    Capital Expenditures 0 -0.023 -0.54 -0.256 -0.416
    Cash From Financing Activities 4.984 8.841 17.933 11.268 10.62
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net 4.984 8.841 18.879 11.268 12.97
    Net Change in Cash -3.199 0.919 0.19 -4.433 1.773
    Cash Interest Paid 0 0.295 0.432 0.471
    Issuance (Retirement) of Debt, Net 0 -0.946 0 -2.35
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -1.675 -10.206 -7.64 -5.002 -2.54
    Cash From Operating Activities -1.899 -8.183 -6.604 -4.731 -2.964
    Cash From Operating Activities 0.043 0.196 0.151 0.103 0.052
    Non-Cash Items 0.29 1.449 1.09 0.549 0.304
    Cash Interest Paid
    Changes in Working Capital -0.557 0.378 -0.205 -0.381 -0.78
    Cash From Investing Activities 0 0 0
    Capital Expenditures 0 0 0
    Cash From Financing Activities 0 4.984 4.984 4.984 4.981
    Issuance (Retirement) of Stock, Net 0 4.984 4.984 4.984 4.981
    Net Change in Cash -1.899 -3.199 -1.62 0.253 2.017
    Issuance (Retirement) of Debt, Net
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Choong (Choon Hau) Individual Investor 24.9593 3747968 3747968 2023-06-23
    Truist Bank Bank and Trust 4.1627 625089 0 2023-06-30 LOW
    Activist Investing, L.L.C. Corporation 2.3912 359066 0 2023-05-01 LOW
    Renaissance Technologies LLC Hedge Fund 0.9031 135610 200 2023-06-30 HIGH
    Lazar (David Elliot) Individual Investor 0.6659 100000 100000 2023-07-26 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.5464 82051 0 2023-06-30 LOW
    Natan (David) Individual Investor 0.4412 66250 16250 2023-10-25 MED
    Ben-Tzvi (Avraham) Individual Investor 0.4412 66250 16250 2023-10-25
    Mcmurdo (Matthew Charles) Individual Investor 0.4412 66250 16250 2023-10-25
    Greenberg (Eric Howard) Individual Investor 0.4412 66250 16250 2023-10-25
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.426 63965 0 2023-06-30 LOW
    McNab (James R Jr) Individual Investor 0.3509 52690 0 2023-05-01
    Chasey (Peter Louis) Individual Investor 0.333 50000 50000 2023-07-26
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.255 38287 0 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 0.1976 29675 29675 2023-06-30 LOW
    Rubin (Marc R) Individual Investor 0.0207 3103 2669 2023-05-01
    Tower Research Capital LLC Hedge Fund 0.0105 1573 -39 2023-06-30 HIGH
    Akers (Joseph A) Individual Investor 0.0079 1185 0 2023-05-01 LOW
    Level Financial Advisors, Inc. Investment Advisor 0.0066 987 0 2023-09-30 LOW
    MacFarlane (M David) Individual Investor 0.0038 572 0 2023-05-01 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Titan Pharmaceuticals, Inc. Company profile

    Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
    Industry: Pharmaceuticals (NEC)

    Suite 505
    400 Oyster Point Blvd
    SAN FRANCISCO
    CALIFORNIA 94080
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    Gold

    2,038.44 Price
    -0.320% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.61 Price
    -0.730% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    37,762.65 Price
    -0.040% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,020.30 Price
    +0.140% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading